234081-98-2

Usage

Uses

Used in Chemical Industry:
Dodecanedioic acid, Mono(1,1-dimethylethyl) ester is used as a key component in the synthesis of polyesters for various applications, such as textiles, packaging materials, and automotive parts. Its high performance and flexibility contribute to the durability and strength of these materials.
Used in Plastics Industry:
This ester compound is used as a plasticizer to enhance the flexibility and workability of plastics. Its hydrolytic stability ensures that the plastic products maintain their properties over time, making them suitable for a wide range of applications, including consumer goods, construction materials, and medical devices.
Used in Resin Production:
Dodecanedioic acid, Mono(1,1-dimethylethyl) ester is employed in the production of resins, which are used in coatings, adhesives, and composite materials. Its presence in these resins improves their performance characteristics, such as adhesion, durability, and resistance to environmental factors.

Upstream product

• 693-23-2 1,12-dodecanedioic acid 
• 75-65-0 tert-butyl alcohol 
• 115-11-7 isobutene 

Downstream Products

• 234081-88-0 11-[(S)-1-Benzyloxycarbonyl-2-((S)-1,2-bis-hexadecylcarbamoyl-ethylcarbamoyl)-ethylcarbamoyl]-undecanoic acid 
• 234081-78-8 11-[(S)-1-Benzyloxycarbonyl-2-((S)-1,2-bis-hexadecylcarbamoyl-ethylcarbamoyl)-ethylcarbamoyl]-undecanoic acid tert-butyl ester 

Relevant academic research and scientific papers

Method for preparing high-purity dodecanedioic acidmono-tert-butyl ester through two-step method

The invention relates to a method for preparing high-purity dodecanedioic acid mono-tert-butyl ester through a two-step method. The method specifically comprises the following steps: (1) dissolving dodecanedioic acid mono-methyl ester and isobutene into an organic solvent, adding an appropriate amount of catalyst at -20 to 0 DEG C, stirring and reacting for 3-5h, removing the catalyst, and concentrating the reaction liquid to obtain a concentrate; (2) dissolving the concentrate obtained in the step (1) into the organic solvent, adding alkali-metal hydroxide, regulating pH to 9-10, stirring andreacting for 2-3h at room temperature, adding diluted hydrochloric acid to regulate to pH to 3 to 4, extracting for 2-3 times with ethyl acetate, washing an organic layer with a saturated salt solution, drying, filtering, and concentrating the anhydrous sodium sulfate to obtain the high-purity dodecanedioic acid mono-tert-butyl ester.

Method for preparing monobutyl dodecyl diacid by one-step high-efficiency method

The invention relates to a method for efficiently preparing dodecanedioic acid, mono(1,1-dimethylethyl) ester by a one-step method. The method specifically comprises the following step of enabling dodecanedioic acid and isobutylene to react in an organic solvent under the action of a catalyst, so as to obtain the dodecanedioic acid, mono(1,1-dimethylethyl) ester, wherein the molar ratio of dodecanedioic acid to the isobutylene is 1:1; the catalyst is a novel graphene/ferriferrous oxide composite nanometer material, and the usage amount of the catalyst is 5mg per mmol of dodecanedioic acid; theisobutylene is preferably an isopropyl ether solution of isobutylene; the organic solvent is preferably dichloromethane and THF; the reaction temperature is preferably -20 to 0 DEG C.

MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

Functional synthetic molecules and macromolecules for gene delivery

The present invention describes a synthetic non-viral vector composition for gene therapy and the use of such compositions for in vitro, ex vivo and/or in vivo transfer of genetic material. The invention proposes a pharmaceutical composition containing 1) a non-cationic amphiphilic molecule or macromolecule and its use for delivery of nucleic acids or 2) a cationic amphiphilic molecule or macromolecule that transforms from a cationic entity to an anionic, neutral, or zwitterionic entity by a chemical, photochemical, or biological reaction and its use for delivery of nucleic acids. Moreover this invention describes the use of these non-viral vector compositions in conjunction with a surface to mediate the delivery of nucleic acids. An additional embodiment is the formation of a hydrogel with these compositions and the use of this hydrogel for the delivery of genetic material. A further embodiment of this invention is the use of a change in ionic strength for the delivery of genetic material.

Charge-reversal amphiphiles for gene delivery

Delivering a missing gene or a functional substitute of a defective gene has the potential to revolutionize current medical care. Of the two gene delivery approaches, viral and synthetic vectors, synthetic cationic vectors possess several practical advant

Trigger lipids inducing pH-dependent liposome fusion

Aspartic acid-derived artificial lipids (ADLs; s indicates the number of the methylene groups, s=2, 4, 6, 8, 10, 12) (Scheme 1) with various carboxyl alkyl chains as head groups are designed and synthesized, which are incorporated into liposome membranes by sonication. Fluorescence resonance energy transfer (FRET) measurements indicate that ADL6, ADL8 and ADL10 have high lipid-mixing ability in the acidic solution. The other ADLs, however, do not induce remarkable liposome fusion at acidic nor neutral pH. The hydrophobicity of the head groups of ADL6, ADL8 and ADL10 is suitable as triggers of membrane fusion.

Non-peptidic liposome-fusion compounds at acidic pH

Liposomes including aspartic acid-derived artificial lipids (ADL) with various carboxy alkyl chains as head groups (ADLn; n indicates the number of the methylene groups, n = 2,4,6,8,10,12) are prepared, in which ADL6 and ADL8 liposomes induce remarkably high lipid-mixing in the acidic region.